Lifespan analysis of 212 transplanted kidney grafts: effects of use of humanized anti-IL-2R monoclonal antibody in graft survival at 1, 3, and 5 years for 108 recipients.

摘要

INTRODUCTION: The use of new drugs and new immunosuppressant schemes, as well as induction therapy with anti-IL-2R monoclonal antibody has significantly contributed to prolonged renal graft survival, especially in cadaveric grafts. However, what has led to this improvement has not been defined yet. OBJECTIVE: Analyze the outcome of induction of humanized anti-IL-2R monoclonal antibodies on 1, 3 and 5 year survivals of 212 renal transplants from 1999 to 2005. METHOD: We analyzed the lifespan of grafts using Kaplan-Meier curves, using a significance level of alpha = 0,05 for 212 renal allografts. RESULTS: The global result for 1, 3 and 5 year survival curves of patients who received the induction therapy was 88%, 86% and 86%, and for recipients who did not receive induction was 81%, 81% and 81%, respectively. Likewise, cadaveric donors who received induction displayed 88%, 88% and 88%, and those who did not receive it 62%, 62% and 62% (p = 0,0089). CONCLUSION: Despite the time and the number of transplants using induction therapy being modest, at 1, 3 and 5 years there was an increased lifespan, especially for cadaveric grafts, among patients who received induction, with IL2Ra antibodies.